|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,165 JPY | +0.85% |
|
+1.54% | +2.74% |
| May. 16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
| May. 15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Takeda Pharmaceutical Company Limited provided earnings guidance for the full year of 2024. The company expects revenue and core revenue of ¥4,350 million, Reported operating profit of ¥225 million. Reported net profit of ¥58 million.
Reported EPS of ¥37 and core EPS of ¥431.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.74% | 41.69B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.81% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 
